Sedef ve Egzama Hastalığının Etimolojisi, Etiyolojisi, Klinik Tipleri ve Tedavisinde Kullanılan İlaçlı ve İlaçsız Yöntemlerin İncelenmesi
Özet
Sedef ve Atopik Egzama (AE), bireylerin fiziksel, psikolojik ve sosyal işlevselliği üzerinde derin etkiler bırakan, kronik ve inflamatuar cilt hastalıklarıdır. Bu hastalıkların tetiklenmesinde genetik yatkınlığın yanı sıra stres, obezite, sigara ve alkol kullanımı ile sabun ve deterjan gibi kimyasal tahriş ediciler önemli rol oynamaktadır. Geleneksel tedavilerde stratum corneum'u nemlendirerek epidermal bariyeri onaran nemlendiriciler, antiinflamatuar etkili kortikosteroidler, D3 vitamini analogları, bağışıklığı baskılayan metotreksat ve siklosporin gibi ajanların yanı sıra fototerapi ve ıslak sargı uygulamalarından yararlanılmaktadır. Ancak geleneksel topikal formülasyonların yağlı doku, kötü koku, düşük penetrasyon ve sistemik yan etki riski gibi dezavantajları mevcuttur. Bu engelleri aşmak amacıyla geliştirilen yeni nesil nano boyutlu ilaç taşıyıcı sistemler dermatolojide yeni bir dönem başlatmıştır. Nanoemülsiyonlar, lipozomlar, niozomlar, katı lipid nanopartiküller ve etozomlar gibi sistemler, aktif maddelerin cildin bariyer katmanlarından geçişini hızlandırarak hedef bölgede kontrollü salım sağlar. Bu yenilikçi sistemler, ilaçların biyoyararlanımını artırırken sistemik toksisiteyi ve cilt tahrişini en aza indirerek hasta uyumunu ve tedavi başarısını önemli ölçüde yükseltmektedir.
Psoriasis and Atopic Eczema (AE) are chronic, inflammatory skin diseases that exert profound impacts on patients' physical, psychological, and social functionalities. In addition to genetic predisposition, lifestyle and environmental risk factors such as stress, obesity, smoking, alcohol consumption, and chemical irritants like soaps or detergents play critical roles in triggering or exacerbating these conditions. Conventional therapeutic strategies leverage moisturizers to hydrate the stratum corneum and repair the epidermal barrier, alongside anti-inflammatory corticosteroids, vitamin D3 analogs, immunosuppressive agents like methotrexate and cyclosporine, phototherapy, and wet-wrap interventions. Nevertheless, traditional topical formulations exhibit distinct limitations, including greasy textures, unpleasant odors, poor skin penetration, and potential systemic adverse effects. To circumvent these challenges, novel nano-sized drug delivery systems have emerged as pioneering alternatives in dermatological science. Advanced carriers such as nanoemulsions, liposomes, niosomes, solid lipid nanoparticles, and ethosomes effectively enhance the transport of active constituents through the skin's formidable barriers to achieve localized, controlled release. By optimizing bioavailability while minimizing systemic toxicity and localized irritation, these next-generation delivery platforms substantially improve patient compliance and clinical outcomes.
Referanslar
Farage MA, Miller KW, Elsner P, et al. Structural characteristics of the aging skin: A review. Cutaneous and Ocular Toxicology. 2007;26: 343-357.
Korting HC, Schäfer-Korting M. Carriers in the topical treatment of skin disease. Drug Delivery. 2010;197: 435-468.
Nair A, Jacob S, Al-Dhubiab B, et al. Basic considerations in the dermatokinetics of topical formulations. Brazilian Journal of Pharmaceutical Sciences. 2013;49: 423-434.
Jacobi A, Mayer A, Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: A systematic review. Dermatology and Therapy. 2015;5: 1-18.
Basko-Plluska JL, Petronic-Rosic V. Psoriasis: epidemiology, natural history, and differential diagnosis. Psoriasis: Targets and Therapy, 2012, 2: 67-76.
Langley R, Krueger G, Griffiths C. Psoriasis: Epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases. 2005;64: ii18-ii23.
Jankovic S, Raznatovic M, Marinkovic J, et al. Risk factors for psoriasis: A case–control study. The Journal of Dermatology. 2009;36: 328-334.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007;370: 263-271.
Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clinics in Dermatology. 2006;24: 438-447.
Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. Northern Clinics of Istanbul. 2016;3(1): 79-82.
Maruani A, Samimi M, Stembridge N, et al. Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. Cochrane Database of Systematic Reviews. 2019;4(4): CD011541
Walling HW, Swick BL. Update on the management of chronic eczema: New approaches and emerging treatment options. Clinical, Cosmetic and Investigational Dermatology. 2010;3: 99-117.
Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy, Asthma & Immunology Research. 2016;8: 181-190.
Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: A systematic review of epidemiological studies. PloS One. 2012;7: e39803.
Eichenfield LF, Ellis CN, Mancini AJ, et al. Atopic dermatitis: Epidemiology and pathogenesis update. Seminars in Cutaneous Medicine and Surgery. 2012;3: 3-5.
Grove D, Reid J, Forbes I. Humoral and cellular immunity in atopic eczema. British Journal of Dermatology. 1975;92: 611-618.
Eyerich K, Novak N. Immunology of atopic eczema: Overcoming the T h1/T h2 paradigm. Allergy. 2013;68: 974-982.
Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Review of Clinical Immunology, 2017;13: 15-26.
Silverberg JI, Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. Journal of Allergy and Clinical Immunology. 2015;135: 721-728.
Pyun BY. Natural history and risk factors of atopic dermatitis in children. Allergy, Asthma & Immunology Research. 2015;7: 101-105.
Mar A, Marks R. The descriptive epidemiology of atopic dermatitis in the community. Australasian Journal of Dermatology. 1999;40: 73-78.
Menné T, Johansen JD, Sommerlund M, et al. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis. 2011;65: 3-12.
Dorynska A, Spiewak R. Epidemiology of skin diseases from the spectrum of dermatitis and eczema. Malaysian Journal of Dermatology. 2012;29: 1-11.
Dessinioti C, Katsambas A. Seborrheic dermatitis: Etiology, risk factors, and treatments: Facts and controversies. Clinics in Dermatology. 2013;31: 343-351.
Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. American Family Physician. 2015;91: 185-190.
Calle Sarmiento PM, Chango Azanza JJ. Dyshidrotic eczema: A common cause of palmar dermatitis. Cureus. 2020;12(10): e10839.
Letić M. Use of sunlight to treat dyshidrotic eczema. JAMA Dermatology. 2013;149: 634-635.
Levin C, Warshaw E. Protein contact dermatitis: Allergens, Pathogenesis, and Management. Dermatitis. 2008;19: 241-251.
Hernández-Bel P, De La Cuadra J, García R, et al. Protein contact dermatitis: Review of 27 cases. Actas Dermo-Sifiliográficas (English Edition). 2011;102: 336-343.
Specht S, Persaud Y. Asteatotic eczema. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022; PMID: 31747214.
Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clinics in Dermatology. 2008;26: 380-386.
Onselen JV. An overview of psoriasis and the role of emollient therapy. British Journal of Community Nursing, 2013;18: 174-179.
Chong M, Fonacier L. Treatment of eczema: corticosteroids and beyond. Clinical Reviews in Allergy & Immunology. 2016;51: 249-262.
Chiricozzi A, Pimpinelli N, Ricceri F, et al. Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatologic Therapy. 2017;30: e12549.
Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. International Scholarly Research Notices. 2014;2014: 354250.
Su Y-H, Fang J-Y. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opinion On Drug Delivery. 2008;5: 235-249.
Trémezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? Dermato-endocrinology. 2011;3: 180-186.
Wadhwa B, Relhan V, Goel K, et al. Vitamin D and skin diseases: A review. Indian Journal of Dermatology, Venereology and Leprology. 2015;81: 344-355.
Mendonca C, Burden A. Current concepts in psoriasis and its treatment. Pharmacology & Therapeutics. 2003;99: 133-147.
Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis. Expert Review of Clinical Immunology. 2015;11: 553-563.
Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation consensus conference. Journal of the American Academy of Dermatology. 2010;62: 838-853.
Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers in Medical Science. 2018;33: 173-180.
Berke R, Singh A, Guralnick M. Atopic dermatitis: An overview. American Family Physician. 2012;86: 35-42.
Comaish J. Tar and related compounds in the therapy of psoriasis. Clinical and Experimental Dermatology. 1981;6: 639-645.
Sekhon S, Jeon C, Nakamura M, et al. Review of the mechanism of action of coal tar in psoriasis. Journal of Dermatological Treatment. 2018;29: 230-232.
Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clinics in Dermatology. 2008;26: 438-447.
Gollnick H. Oral retinoids-efficacy and toxicity in psoriasis. British Journal of Dermatology. 1996;135: 6-17.
LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatric Dermatology. 2019;36: 36-65.
Behrendt H, Ring J. Histamine, antihistamines and atopic eczema. Clinical & Experimental Allergy. 1990;20: 25-30.
Jyothi SL, Krishna L, Shirin VK, et al. Drug delivery systems for the treatment of psoriasis: Current status and prospects. Journal of Drug Delivery Science and Technology. 2021;62(3): 102364.
Shruti G, Prabha S, Padmini R. Emerging topical drug delivery approaches for the treatment of Atopic dermatitis. Journal of Cosmetic Dermatology. 2022;21: 536–549.
Vincent N, Ramya DD, Vedha HB. Progress in Psoriasis therapy via novel drug delivery systems. Dermatology Reports. 2014;6: 51-54.
Nordin UUM, Ahmad N, Salim N, et al. Lipid-based nanoparticles for psoriasis treatment: A review on conventional treatments, recent works, and future prospects. RSC Advances. 2021;46: 29080-29101.
